Bayer, CRISPR Therapeutics Launch JV to Develop CRISPR/Cas9 Treatments

Dec 21, 2015

|

NEW YORK (GenomeWeb) – Switzerland's CRISPR Therapeutics and Germany's Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting.

The deal brings together Bayer's experience in protein engineering and knowledge of human diseases with CRISPR Therapeutics' CRISPR/Cas9 intellectual property and genome editing expertise, the firms said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Commission's First Meeting

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

More Scrutiny

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Web of Neutrophil DNA

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

Science Explores Method to Infer Genotype-by-Environment Interactions

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.

Menu